Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1 < 10%

Condition:   Non-small Cell Lung Cancer Intervention:   Drug: CA and Nivolumab Sponsor:   National Cancer Center, Korea Not yet recruiting

Source: ClinicalTrials.gov - January 17, 2019 Category: Research Source Type: clinical trials